Gain Therapeutics: Phase 1 Readout Awaits For Parkinson’s Drug With Great Potential (GANX)

Thesis

I covered Gain Therapeutics, Inc. (NASDAQ:GANX) some months ago, having found both the company’s drug-discovery platform Magellan and drug candidate GT-02287, the second drug candidate with best-in-class potential which has been generated by that platform, fascinating.

I

Read the full article here